News Braveheart, AAVantgarde rounds head recent biofinancings Our latest crop of biotech financings has nine-figure rounds for Braveheart and AAVantgarde, with Azalea Therapeutics and NEOK Bio also raising funds.
News Apogee buy delivers eczema trial win for AbbVie AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.